Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06520-8264, USA.
Vaccine. 2010 Nov 3;28(47):7501-6. doi: 10.1016/j.vaccine.2010.09.013. Epub 2010 Sep 17.
Rotavirus vaccine was recommended for use in US infants to prevent rotavirus gastroenteritis (RGE) in February 2006. This matched case control study assessed the effectiveness of rotavirus vaccine in preventing hospitalization of young. Cases were vaccine-eligible children 8 weeks-3 years of age, hospitalized due to laboratory-confirmed RGE. Cases (n=42) were matched to 2 control groups: (a) hospitalized controls (n=80): children hospitalized for reasons other than RGE, matched to the cases by age and time of presentation and (b) community controls (n=73): non-hospitalized children matched by age and medical practice. Adjusted vaccine effectiveness against hospitalization with RGE in vaccine eligible children receiving at least one dose of vaccine was 94.3% (95% C.I.: 55.4%-99.3%; p=0.006) for hospitalized controls and 96.9% (95% C.I.: 59.4%-99.8%; p=0.008) for community controls.
轮状病毒疫苗于 2006 年 2 月被推荐用于美国婴儿，以预防轮状病毒胃肠炎（RGE）。这项病例对照研究评估了轮状病毒疫苗预防幼儿住院的效果。病例为接种疫苗合格的 8 周至 3 岁儿童，因实验室确诊的 RGE 住院。病例（n=42）与 2 个对照组匹配：（a）住院对照组（n=80）：因 RGE 以外的其他原因住院的儿童，与病例按年龄和就诊时间匹配；（b）社区对照组（n=73）：非住院儿童按年龄和医疗实践匹配。在接受至少一剂疫苗的接种合格儿童中，轮状病毒疫苗对 RGE 住院的调整疫苗有效性为 94.3%（95%CI：55.4%-99.3%；p=0.006），对住院对照组为 96.9%（95%CI：59.4%-99.8%；p=0.008），对社区对照组为 96.9%（95%CI：59.4%-99.8%；p=0.008）。
